What is HC Wainwright’s Estimate for KYMR FY2026 Earnings?

Kymera Therapeutics, Inc. (NASDAQ:KYMR) – Analysts at HC Wainwright boosted their FY2026 earnings per share estimates for Kymera Therapeutics in a research report issued on Thursday, June 26th. HC Wainwright analyst A. Fein now expects that the company will post earnings of ($3.24) per share for the year, up from their previous forecast of ($3.35). HC Wainwright currently has a “Buy” rating and a $60.00 target price on the stock. The consensus estimate for Kymera Therapeutics’ current full-year earnings is ($2.79) per share. HC Wainwright also issued estimates for Kymera Therapeutics’ FY2027 earnings at ($3.53) EPS, FY2028 earnings at ($3.58) EPS and FY2029 earnings at ($3.23) EPS.

A number of other analysts also recently issued reports on the company. Jefferies Financial Group set a $64.00 price objective on Kymera Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, June 25th. BTIG Research reissued a “buy” rating and issued a $59.00 target price on shares of Kymera Therapeutics in a report on Thursday. Morgan Stanley upgraded shares of Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $49.00 to $79.00 in a research report on Tuesday, June 3rd. Stifel Nicolaus initiated coverage on shares of Kymera Therapeutics in a research note on Tuesday, May 20th. They set a “buy” rating and a $55.00 price target on the stock. Finally, Citigroup assumed coverage on shares of Kymera Therapeutics in a research note on Thursday, March 13th. They issued a “buy” rating and a $52.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $59.61.

Kymera Therapeutics Stock Down 1.1%

KYMR opened at $43.64 on Monday. The company has a market capitalization of $2.84 billion, a PE ratio of -14.08 and a beta of 2.07. The firm has a 50-day simple moving average of $37.41 and a two-hundred day simple moving average of $35.77. Kymera Therapeutics has a 52 week low of $19.45 and a 52 week high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last released its earnings results on Friday, May 9th. The company reported ($0.82) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.10. Kymera Therapeutics had a negative net margin of 409.07% and a negative return on equity of 30.11%. The firm had revenue of $22.10 million for the quarter, compared to the consensus estimate of $11.38 million. During the same quarter in the previous year, the firm earned ($0.69) earnings per share. The company’s quarterly revenue was up 114.6% compared to the same quarter last year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. KBC Group NV increased its holdings in Kymera Therapeutics by 15.2% in the first quarter. KBC Group NV now owns 2,479 shares of the company’s stock valued at $68,000 after buying an additional 328 shares in the last quarter. Summit Investment Advisors Inc. grew its position in shares of Kymera Therapeutics by 9.0% during the 4th quarter. Summit Investment Advisors Inc. now owns 4,912 shares of the company’s stock valued at $198,000 after acquiring an additional 406 shares during the period. Comerica Bank grew its position in shares of Kymera Therapeutics by 3.6% during the 1st quarter. Comerica Bank now owns 21,374 shares of the company’s stock valued at $585,000 after acquiring an additional 743 shares during the period. Hsbc Holdings PLC increased its stake in shares of Kymera Therapeutics by 6.1% in the 1st quarter. Hsbc Holdings PLC now owns 18,547 shares of the company’s stock valued at $508,000 after purchasing an additional 1,064 shares in the last quarter. Finally, State of Wyoming acquired a new position in Kymera Therapeutics in the 4th quarter worth about $45,000.

Insider Activity at Kymera Therapeutics

In other news, Director Bros. Advisors Lp Baker purchased 655,500 shares of the company’s stock in a transaction on Monday, June 30th. The shares were acquired at an average price of $44.00 per share, for a total transaction of $28,842,000.00. Following the purchase, the director owned 6,117,295 shares in the company, valued at $269,160,980. This trade represents a 12.00% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Nello Mainolfi sold 30,000 shares of Kymera Therapeutics stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $49.00, for a total value of $1,470,000.00. Following the sale, the chief executive officer directly owned 660,482 shares of the company’s stock, valued at $32,363,618. This trade represents a 4.34% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 48,349 shares of company stock worth $2,334,301. 16.01% of the stock is owned by company insiders.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.